US Patent

US10245269 — Salt form of a human histone methyltransferase EZH2 inhibitor

Method of Use · Assigned to Eisai R&D Management Co Ltd · Expires 2033-04-11 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a specific salt form of a compound that inhibits the human histone methyltransferase EZH2 enzyme.

USPTO Abstract

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4â²-(morpholinomethyl)-[1,1â²-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2737`	—	tazemetostat-hydrobromide

Patent Metadata

Patent number: US10245269
Jurisdiction: US
Classification: Method of Use
Expires: 2033-04-11
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.